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Aims An implantable cardioverter-defibrillator (ICD) is recommended for reducing the risk of sudden cardiac death (SCD)
in myocardial infarction (MI) patients with a left ventricular ejection fraction (LVEF) ≤ 30%, as well as patients with a
LVEF ≤ 35% and heart failure symptoms. Diabetes and/or impaired kidney function may confer additional SCD risk.
We assessed the association between these two risk factors with SCD and non-SCD among MI survivors taking
account of age and LVEF.
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Methods
and results
A total of 17 773 patients from the High-Risk MI Database were evaluated. Overall, diabetes and estimated glomerular
filtration rate < 60 mL/min/1.73 m2, individually and together, conferred a higher risk of SCD [adjusted competing risk:
hazard ratio (HR) 1.23, 1.23, and 1.32, respectively; all P< 0.03] and non-SCD (HR 1.34, 1.52, and 2.13, respectively;
all P< 0.0001). Annual SCD rates in patients with LVEF > 35% and with diabetes, impaired kidney function, or both
(2.0%, 2.5% and 2.7%, respectively) were comparable to rates observed in patients with LVEF 30–35% but no such
risk factors (1.7%). However, these patients had also similarly higher non-SCD rates, such that the ratio of SCD
to non-SCD was not increased. Importantly, this ratio was mostly dependent on age, with higher overall ratios in
youngest subgroups (0.89 in patients < 55 years vs. 0.38 in patients ≥ 75 years), regardless of risk factors.
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Conclusion Although MI survivors with LVEF > 35% with diabetes, impaired kidney function, or both are at increased risk of
SCD, the risk of non-SCD risk is even higher, suggesting an extension of the current indication for an ICD to them is
unlikely to be worthwhile. MI survivors with low LVEF and aged < 55 years are likely to have the greatest potential
benefit from ICD implantation.
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Introduction
Current guidelines1–3 recommend an implantable
cardioverter-defibrillator (ICD) in myocardial infarction (MI)
patients with left ventricular ejection fraction (LVEF) ≤ 35% and
symptomatic heart failure (HF), or with LVEF ≤ 30%, even if asymp-
tomatic, ≥ 40 days after their index event (≥ 90 days if coronary
revascularization occurs). However, reduced LVEF, as a standalone
risk stratifier for guiding ICD implantation, is a relatively poor
predictor of sudden cardiac death (SCD)4 and most SCDs occur
in patients with LVEF > 35%, i.e. in patients with preserved or only
moderately reduced systolic function.4
Diabetes5 and impaired kidney function,6 two of the most
common co-morbidities among patients with MI, are associated
with high rates of cardiovascular and all-cause death. There is
substantial evidence indicating the association between diabetes
and SCD in patients with atherosclerotic coronary artery disease7
or following MI,8 although little is known regarding its interplay with
impaired kidney function, a common condition in diabetic patients.
Nevertheless, in a large cohort of HF patients, the proportion
of overall deaths that was attributable to SCD was lower among
individuals with diabetes or impaired kidney function, as compared
to those without these co-morbidities, suggesting a high level of
competing risk of other death modalities in these patients.9
Recently, the results of the Danish Study to Assess the Efficacy of
ICDs in Patients with Non-ischaemic Systolic Heart Failure (DAN-
ISH), conducted in patients with non-ischaemic cardiomyopathy
and low LVEF, emphasized the major impact of age on benefit of
ICD treatment.10 This finding is seemingly the consequence of the
higher competing risk of non-SCD in older patients. ICD efficacy
may also be reduced among patients with multiple co-morbidities
and impaired kidney function.11–13 The interplay between age and
diabetes/impaired kidney function, all of which appear as impor-
tant contributors to the competing risk of non-SCD, has not been
investigated in detail.
In the present study, we examined the associations between dia-
betes and/or impaired kidney function with the risk of SCD and
non-SCD, and their relative rates, in survivors of MI complicated
by HF, left ventricular dysfunction or both in the pooled population
of four large clinical trials14 conducted before the era of primary
prevention ICD therapy. In addition, these associations were eval-
uated according to LVEF and age given that these variables could
represent major contributors to both the absolute and relative risk
of SCD and non-SCD.
Methods
High-risk acute myocardial infarction
trials pooling project
The rationale for selecting and pooling the four trials included in this
analysis has been published elsewhere.14 The High-Risk MI Database
Initiative included: the Effect of Carvedilol on Outcome after Myocar-
dial Infarction in Patients with Left Ventricular Dysfunction trial
(CAPRICORN),15 the Eplerenone Neurohormonal Efficacy and Sur-



















































































.. Angiotensin II Antagonist Losartan (OPTIMAAL),17 and the Valsartan
in Acute Myocardial Infarction trial (VALIANT).18
Each trial enrolled patients with left ventricular systolic dysfunction
(LVEF < 40%), HF or both between 12 h and 21 days after acute MI
(with the exception of OPTIMAAL,17 which included patients with
LVEF < 35%, left ventricular enlargement, or new anterior Q-waves
if HF was absent). In total, 28 771 patients were enrolled overall (1959
in CAPRICORN; 6632 in EPHESUS; 5477 in OPTIMAAL, and 14 703 in
VALIANT) with a mean follow-up of 2.7 years. Each trial was random-
ized and double-blinded. In two trials, patients were assigned equally
to placebo or active therapy (carvedilol or eplerenone)15,16 in addition
to usual treatment. In the other two trials, patients were random-
ized to experimental therapy (losartan or valsartan) or active control
(captopril).17,18 VALIANT18 additionally featured a third treatment arm
(captopril plus valsartan).
Baseline demographics, risk factors and clinical characteristics at the
time of MI were recorded for each trial. An expert endpoint committee
adjudicated all events in each of the trials, which had similar definitions
of various endpoints.14
With regard to the studied endpoints, SCD and non-SCD were
the pre-specified outcomes in the present analyses. All major clinical
trials included in this database had independent blinded endpoint
committees that adjudicated the essential primary and secondary
study endpoints.15–18 The definition of SCD varied across studies:
depending on the study, SCD referred to witnessed deaths due to
an identified arrhythmia, cardiac arrest or cardiovascular collapse
without premonitory HF or MI and/or death during or after successful
resuscitation from sudden cardiac arrest.
Definition of history of diabetes
and impaired kidney function
Data pertaining to history of diabetes were collected by the study
investigators at baseline, based on the treating physician’s diagnosis
of diabetes. Chronic kidney disease was defined by the presence
of kidney damage or an estimated glomerular filtration rate (eGFR)
< 60 mL/min/1.73 m2 of body surface area for a period ≥ 3 months.19
eGFR was calculated using the four-component Modification of Diet in
Renal Disease equation.19
Statistical methods
Of the 28 771 randomized patients, 1959 (6.8%) had incomplete data
for time-to-event outcomes. LVEF was not reported in 8857 patients,
while eGFR was missing in a further 182 patients. Altogether, 17 773
patients (61.8%) were available for the present analysis.
Continuous variables are expressed as mean (±standard deviation)
and categorical variables as numbers and percentages. Baseline char-
acteristics were defined in the whole sample as well as according to
four subgroups characterized by the presence/absence of diabetes and
impaired kidney function: (i) no diabetes and no impaired kidney func-
tion; (ii) diabetes and no impaired kidney function; (iii) no diabetes and
impaired kidney function; (iv) diabetes and impaired kidney function.
Differences were evaluated within three LVEF strata (LVEF < 30%, LVEF
30–35%, and LVEF > 35%) according to current guideline indications
for primary prevention ICD therapy after acute MI,1,2 using ANOVA
and chi-square for trend as appropriate.
Kaplan–Meier survival curves were used to illustrate the distribu-
tion of SCD and non-SCD in a follow-up time scale, while a log-rank
analysis was performed to compare survival curves between groups.
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Competing risk regression based on the Fine–Gray proportional
sub-hazards model was performed20 with resulting associations
expressed as hazard ratios (HR) and their 95% confidence interval
(CI). As detailed previously, these models were adjusted for the fol-
lowing three a priori selected models21: (i) model 1 (age and gender);
(ii) model 2 (age, gender, presence of HF signs/symptoms, LVEF strata,
Killip class ≥ 3, history of angina, MI, HF, hypertension, renal failure,
chronic obstructive pulmonary disease, peripheral artery disease, sys-
tolic and diastolic blood pressure, and heart rate); (iii) model 3: model
2 plus treatment at baseline (digoxin, angiotensin-converting enzyme
inhibitors/angiotensin receptor blockers, beta-blockers, diuretics,
aspirin, calcium channel blockers, statin, or any lipid-lowering agent
intake). A possible interaction between risk factor subgroups and LVEF
with clinical outcome was assessed by introducing an interaction term
(risk factor subgroups*LVEF < 30/LVEF 30–35%/LVEF > 35%, with
LVEF < 30% as reference) within models.
In order to adjust Kaplan–Meier survival curves, stabilized inverse
probability of treatment weighting methods (sIPTW), a type of propen-
sity score adjustment, were used to address confounding by observed
covariates.22 A multinomial logistic regression model was developed,
with diabetes/eGFR as outcome and the aforementioned covariates as
predictors. In this model, each subject’s weight, called stabilized weight,
is equal to the inverse of the probability of being in the group to which
the subject belongs (probability predicted from the model), multiplied
by the marginal probability of the group in the overall population. The
balance between the four diabetes/eGFR groups was assessed by cal-
culating the absolute standardized mean difference before and after
weighting. Differences between survival curves were analysed using the
robust log-rank test.
Annual SCD rates were obtained from these curves during the entire
follow-up period after randomization, both in the whole cohort as well
as in LVEF and age subsets (< 55, 55–64, 65–74, and ≥ 75 years). A sup-
plementary analysis was performed to assess annual SCD rates during
the late phase of MI (i.e. > 40 days after the index event, by exclud-
ing the time frame during the course of which ICD demonstrated no
beneficial effect).1
The subgroup with missing LVEF at baseline and complete follow-up
(n = 8694, 30.2%) was also investigated to assess outcomes according
to diabetic status and eGFR.
A P-value < 0.05 was considered significant. Statistical analyses were
performed using the SPSS package version 23.0 (SPSS Inc., Chicago, IL,




The study cohort included 17 773 patients, 3825 with LVEF
< 30% (21.5%), 7807 with LVEF 30–35% (44%), and 6141 with
LVEF > 35% (34.5%); mean age was 64±11 years and 70% were
male. Compared to patients without diabetes and/or eGFR
< 60 mL/min/1.73 m2, patients exhibiting both these baseline char-
acteristics were older and had a higher heart rate, systolic blood
pressure and Killip class, irrespective of LVEF subgroup. They also
were more likely to have prior angina or a previous MI, a previous
episode of HF hospitalization or renal insufficiency, and more likely
to be on diuretics or digoxin (Table 1).
After applying the sIPTW method, the absolute standardized



















































































.. substantial improvement in balance across treatment groups, both
in the whole population (online supplementary Table S1) as well as
in the LVEF subsets (data not shown).
Impact of diabetes, impaired kidney
function, and their interplay
on outcomes in the whole cohort
During a median follow-up of 644 (443–844) days, 1052 patients
(5.9%) died of SCD while 2090 patients (11.8%) died of non-SCD.
Among non-SCDs, 1642 (78.6%) were of cardiovascular ori-
gin, with the following adjudicated causes: HF (n = 675, 32.3%),
MI (n = 248, 11.9%) and stroke (n = 142, 6.8%). Using adjusted
Kaplan–Meier curves, patients with both diabetes and impaired
kidney function (eGFR < 60 mL/min/1.73 m2) had higher rates of
SCD and non-SCD compared to patients with either diabetes or
eGFR < 60 mL/min/1.73 m2, or neither of the latter (Figure 1). Simi-
lar findings were also observed using the unadjusted Kaplan–Meier
method (online supplementary Figure S1).
In adjusted, competing-risk, survival analysis (model 3 adjust-
ment), diabetes was a significant predictor of SCD (HR 1.23,
95% CI 1.03–1.46, P = 0.023) and non-SCD (HR 1.34, 95% CI
1.17–1.53, P< 0.0001). Similar associations were also observed
for eGFR < 60 mL/min/1.73 m2 (HR for SCD: 1.23, 95% CI
1.04–1.45, P = 0.014; HR for non-SCD: 1.52, 95% CI 1.35–1.71,
P< 0.0001). Higher risks of each type of death were observed
for patients with both co-morbidities (HR for SCD: 1.32, 95% CI
1.09–1.61, P = 0.005; HR for non-SCD: 2.13, 95% CI 1.87–2.43,
P< 0.0001). Overall, the risk associated with either co-morbidity
alone or together was greater for non-SCD than for SCD (Table 2).
When considering late phase MI (> 40 days after MI), similar
results were observed (online supplementary Table S2). In patients
whose LVEF was not available at baseline, similar trends were
observed although the precision of the estimations was lower given
the smaller sample size (online supplementary Table S3).
Impact of diabetes, impaired kidney
function, and their interplay according
to left ventricular ejection fraction
A significant interaction between various combinations of diabetes
and eGFR (neither, one or other, both) and LVEF strata was
documented for both SCD and non-SCD (P = 0.024 and P = 0.008,
respectively) (online supplementary Table S4). Regarding SCD, this
interaction across LVEF strata appeared to be mainly related to
the heterogeneity of the respective associations with risk factor
subgroups. However, the associations for the combined condition
of diabetes and eGFR < 60 mL/min/1.73 m2 remained stable across
LVEF strata (with HRs ranging from 1.29 to 1.34). In contrast, for
non-SCD, the associations with this combined condition increased
with higher LVEF (HR 1.68, 95% CI 1.36–2.07 for LVEF < 30% to
HR 2.87, 95 CI 2.27–3.62 for LVEF > 35%) (online supplementary
Table S4).
When calculating the annual SCD rate with respect to the pres-
ence or absence of diabetes and/or of eGFR < 60 mL/min/1.73 m2,
© 2019 The Authors
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Figure 1 Adjusted Kaplan–Meier survival curves in the whole cohort. Sudden cardiac death (A) and non-sudden cardiac death (B) rates
among the four subgroups [no diabetes/estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2, diabetes/eGFR ≥ 60 mL/min/1.73 m2,
no diabetes/eGFR < 60 mL/min/1.73 m2, and diabetes/eGFR < 60 mL/min/1.73 m2] in the whole population.
according to LVEF strata (Figure 2), there was an overall annual SCD
rate of at least 1% for all subgroups. Patients with LVEF < 30% and
one or both risk factors had the highest SCD rates. Among patients
with LVEF > 35% and one or both risk factors, the annual SCD
rate was approximately 2% (ranging from 2.0% to 2.7%), which
was comparable or even higher to that documented for patients
with LVEF 30–35% and no diabetes or eGFR < 60 mL/min/1.73 m2
(1.7%) (Figure 2). However, the SCD/non-SCD ratio tended to be
lower in patients with LVEF > 35% (0.35 ratio for LVEF > 35%
vs. approximately 0.50 ratio for lower LVEF strata), especially in
patients with both diabetes and eGFR < 60 mL/min/1.73 m2 (ratio
0.28) (Figure 2).
Similar findings were observed in the late phase analysis (online
supplementary Table S5). Rates of SCD and non-SCD as well as
their ratios in patients without available LVEF values at baseline
were comparable to the intermediate LVEF stratum (i.e. LVEF
30–35%) (online supplementary Table S6).
Impact of diabetes, impaired kidney
function, and their interplay according
to age
When calculating the annual SCD rate according to the presence or
absence of diabetes and/or eGFR < 60 mL/min/1.73 m2 according
to age strata (< 55, 55–64, 65–74, or ≥ 75 years) (Figure 3), the
overall annual SCD rate was at least 1% for all subgroups. An
increase in SCD rates was observed with increasing age categories
(1.7% to 3.6%), but this was less substantial than the rise in
non-SCD rates (1.9% to 9.4%). As a result, the ratio between risk of
SCD (numerator) and risk of non-SCD (denominator) decreased
substantially with increasing age, from 0.89 in the youngest patients
to 0.38 in patients aged ≥ 75 years (Figure 3). SCD/non-SCD ratios
did not appear to be significantly modified by the presence or
absence of diabetes and/or eGFR < 60 mL/min/1.73 m2 within the























































We evaluated the association between diabetes and/or impaired
kidney function with the risk of adjudicated SCD and non-SCD
in a cohort of 17 773 MI survivors prior to the era of primary
prevention ICD use, and stratified according to the severity of
left ventricular dysfunction and age. Overall, our results show
that diabetes and/or impaired kidney function independently confer
a higher risk of both SCD and non-SCD. However, the most
noteworthy result of our analysis is that younger age was the
factor most strongly associated with a higher SCD/non-SCD ratio,
to a much greater extent than diabetes and/or impaired kidney
function. Since a lower SCD/non-SCD ratio is unlikely to identify
patients with an overall mortality reduction from ICD treatment,
this finding suggests a pattern of potential age-dependent loss
of ICD benefit, similar to that observed in the DANISH trial.
Although the latter was performed in patients with non-ischaemic
cardiomyopathy, it looks like the same outcome might be expected
in older patients after acute MI.
The detailed analysis herein, in a very large dataset of post-MI
patients, treated before the era of primary prevention ICD ther-
apy, may provide useful insights on risk stratification in clinical
practice based on the complex interplay of diabetes, impaired
kidney function, LVEF, and age. Indeed, post-MI patients with
diabetes and/or impaired kidney function and LVEF > 35% have
an absolute risk of SCD similar to patients with LVEF 30–35%
in the absence of these co-morbidities, although they display a
lower SCD/non-SCD ratio, particularly if both risk factors are
present (ratio < 0.3), suggesting that the ICD treatment effect
may be significantly attenuated in this population. In contrast,
post-MI patients aged < 55 years with diabetes and/or impaired
kidney function have a relatively high risk of SCD, irrespective
of LVEF, while maintaining a high SCD/non-SCD ratio (close to
1); this implies that there could be an overall mortality bene-
fit from an ICD in younger patients with such co-morbidities
following MI.
© 2019 The Authors
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Table 2 Association of the interplay of diabetes and impaired kidney function (estimated glomerular filtration rate
< 60 mL/min/1.73 m2) with sudden cardiac death and non-sudden cardiac death in univariable and multivariable
competing risk model analysis
Competing risk model
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
SCD as outcome, non-SCD
as competing risk event
Non-SCD as outcome, SCD
as competing risk event
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable analysis <0.0001 <0.0001
No diabetes/eGFR ≥ 60 Reference Reference
Diabetes/eGFR ≥ 60 1.42 (1.19–1.68) <0.0001 1.57 (1.38–1.79) <0.0001
No diabetes/eGFR < 60 1.67 (1.43–1.95) <0.0001 2.52 (2.26–2.82) <0.0001
Diabetes/eGFR < 60 2.03 (1.70–2.42) <0.0001 3.76 (3.34–4.23) <0.0001
Model 1 <0.0001 <0.0001
No diabetes/eGFR ≥ 60 Reference Reference
Diabetes/eGFR ≥ 60 1.38 (1.16–1.64) 0.0002 1.48 (1.30–1.69) <0.0001
No diabetes/eGFR < 60 1.45 (1.23–1.70) <0.0001 1.73 (1.54–1.94) <0.0001
Diabetes/eGFR < 60 1.79 (1.49–2.16) <0.0001 2.70 (2.39–3.06) <0.0001
Model 2 0.0009 <0.0001
No diabetes/eGFR ≥ 60 Reference Reference
Diabetes/eGFR ≥ 60 1.26 (1.06–1.50) 0.009 1.36 (1.19–1.56) <0.0001
No diabetes/eGFR < 60 1.29 (1.10–1.53) 0.002 1.58 (1.40–1.78) <0.0001
Diabetes/eGFR < 60 1.42 (1.17–1.72) 0.0004 2.21 (1.94–2.51) <0.0001
Model 3 0.013 <0.0001
No diabetes/eGFR ≥ 60 Reference Reference
Diabetes/eGFR ≥ 60 1.23 (1.03–1.46) 0.023 1.34 (1.17–1.53) <0.0001
No diabetes/eGFR < 60 1.23 (1.04–1.45) 0.014 1.52 (1.35–1.71) <0.0001
Diabetes/eGFR < 60 1.32 (1.09–1.61) 0.005 2.13 (1.87–2.43) <0.0001
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection fraction; SCD, sudden cardiac death.
The present analysis refers to the entire follow-up period starting from randomization.
Model 1 is adjusted for age and gender.
Model 2 is adjusted for age, gender, Killip class ≥ 3, heart failure signs/symptoms, LVEF < 30/LVEF 30–35%/LVEF > 35%, co-morbidities (history of angina, myocardial infarction,
heart failure, hypertension, renal failure, chronic obstructive pulmonary disease, peripheral artery disease), and clinical variables (systolic and diastolic blood pressure, heart
rate).
Model 3 is adjusted for age, gender, Killip class ≥ 3, heart failure signs/symptoms, LVEF < 30/LVEF 30–35%/LVEF > 35%, co-morbidities (history of angina, myocardial infarction,
heart failure, hypertension, renal failure, chronic obstructive pulmonary disease, peripheral artery disease), clinical variables (systolic and diastolic blood pressure, heart rate),
and treatment at baseline (digoxin, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, diuretics, aspirin, beta-blockers, calcium channel blockers, statin,
or any lipid-lowering agent intake).
Risk of sudden cardiac death, possible
implantable cardioverter-defibrillator
benefits, and competing risk issues
in patients with diabetes and/or impaired
kidney function beyond left ventricular
dysfunction
Currently, the single most widely used criterion for ICD implan-
tation is a severely depressed LVEF (i.e. < 30% or 35%),1,2 mainly
owing to its ability to predict absolute risk of SCD. However, cur-
rent mortality rates (including sudden death rates) even without
an ICD are lower today in the setting of better medical therapy
for systolic HF.23 This emphasizes the need for the identification of
patients currently at higher absolute risk of SCD. In keeping with
this line of reasoning, the present results would suggest that there
may be a subgroup of patients with LVEF > 35% and risk factors

























.. thus likely to benefit from ICD implantation. However, the recent
results of the DANISH trial10 challenged the above concept based
on absolute risk and emphasized the importance of competing risk
in patients with LVEF ≤ 35% and non-ischaemic dilated cardiomy-
opathy. This concept is also very likely to be highly relevant in
ischaemic HF.
In line with the present results, data from a cohort of 3276
MI survivors showed a similar risk of SCD in patients with dia-
betes and LVEF > 35% to that seen in patients without diabetes
with LVEF ≤ 35% (4.1% vs. 4.9%).8 In this previous study, non-SCD
risk was disproportionally higher in patients without diabetes and
LVEF ≤ 35% when compared to patients with diabetes and LVEF
> 35% (13.1% vs. 4.7%).8 In the present cohort, impaired kid-
ney function was found to modify this risk pattern since patients
with LVEF > 35% with both diabetes and impaired kidney func-
tion had a much higher risk of non-SCD (9.7%/year) than patients
with only diabetes (3.7%/year) or patients with LVEF < 30% but
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Figure 2 Annual sudden cardiac death (SCD) and non-SCD rates (and their ratio) according to left ventricular ejection fraction (LVEF)
subgroups. eGFR, estimated glomerular filtration rate.
without diabetes/impaired kidney function (6.1%/year). In addition,
the risk for non-SCD was found to be systematically higher in
patients with impaired kidney function, with or without diabetes
(confirmed by survival model results). This is in keeping with an
analysis performed in 6378 HF patients from the Studies of Left
Ventricular Dysfunction (SOLVD) (75% with previous MI) show-
ing a disproportionally increased risk of non-arrhythmic death in
patients with more advanced renal dysfunction.24 Similarly, in the
Seattle Proportional Risk Model (derived from a large ambula-
tory HF cohort with slightly more than 50% of patients with an
ischaemic aetiology),9 both diabetes and creatinine levels were
associated with a lower proportion of SCD (vs. non-SCD) (multi-
variable odds ratio 0.75 and 0.65, respectively; P< 0.0001 for both).
In addition, a meta-analysis of the Multicenter Automatic Defibril-
lator Implantation Trial (MADIT)-I,25 MADIT-II,26 and Sudden Car-
diac Death in Heart Failure Trial (SCD-HeFT)27 showed that the
ICD treatment effect was significantly greater in patients with eGFR
≥ 60 mL/min/1.73 m2 (adjusted HR 0.49, 95% CI 0.24–0.95) than
in patients with eGFR < 60 mL/min/1.73 m2 (adjusted HR 0.80,
95% CI 0.40–1.53; Pinteraction <0.001).






























. Medicare-based registry also suggested the cardinal importance of
impaired kidney function in subsequent outcome following ICD
implantation.28
Overall, these data strongly suggest that competing risks of
non-arrhythmic mortality in patients with impaired kidney func-
tion may blunt the potential benefit from prevention of arrhythmic
death. Our results further show that the disproportional increase
in non-SCD over SCD related to impaired kidney function persists
in patients with LVEF > 35% and in patients with diabetes, suggest-
ing that, similarly, a lesser ICD treatment effect would be observed
in these groups.
Competing risk of mode of death
and benefit from implantable
cardioverter-defibrillator therapy
according to age
Decreasing SCD/non-SCD ratios, according to age, have been
reported in an analysis of the Amiodarone Trialists Metanalysis
(ATMA),29 a database including 6252 patients from MI and HF
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Figure 3 Annual sudden cardiac death (SCD) and non-SCD rates (and their ratio) in the four subgroups according to age categories. eGFR,
estimated glomerular filtration rate.
trials, and in MI survivors in the Trandolapril Cardiac Evaluation
(TRACE) trial.30 Importantly, in this latter analysis, while absolute
SCD rates increased with age (4.8%, 7.3%, 10.5%, and 14.2% in
patients aged < 56, 56–65, 66–75, ≥ 76 years, respectively), likely
because the TRACE trial was performed in the early 1990s, with
less use of effective reperfusion strategies, SCD/non-SCD ratios
still decreased with age (1.44, 1.09, 0.76, and 0.55, respectively).
The MADIT-II trial did not provide evidence against ICD implan-
tation in patients aged ≥ 75 years since no significant interaction
with age was identified.31 However, the SCD-HeFT trial, includ-
ing patients with ischaemic and non-ischaemic aetiologies, failed to
demonstrate a significant treatment effect in patients ≥ 65 years.27
Similarly, the more contemporary DANISH trial, assessing the
effect of ICD implantation in patients with non-ischaemic car-
diomyopathy, showed a significantly lower treatment effect in older
patients (Pinteraction = 0.009).
10 It should be emphasized that people
aged > 75 years are typically poorly represented or even excluded
from ICD trials.32 In our cohort, the subgroup of patients aged




























. and number of events (293 SCDs and 845 non-SCDs), and much
larger than patients included in primary prevention ICD trials.
Future directions
These results refine our understanding of the use of co-morbidities
such as diabetes and impaired kidney function as risk stratifiers
for SCD following MI. Although these co-morbidities confer a
high risk of SCD, the risk of non-SCD is even greater; thus,
it is likely that additional predictors of SCD should be used to
refine risk stratification in these conditions. This is especially
true in older individuals, since the ratio of SCD to non-SCD is
lower than in younger patients. Consequently, the time has likely
come to go beyond the current principal criterion for implan-
tation of ICD, namely LVEF ≤ 35%. However, in patients aged
< 55 years, since the SCD/non-SCD ratio remains in the vicin-
ity of 1, diabetes and/or impaired kidney function could be useful
additional risk stratifiers. Evidence in this respect may have been
provided by the Multicenter Automatic Defibrillator Implantation
© 2019 The Authors
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Trial With Subcutaneous Implantable Cardioverter Defibrillator
(MADIT S-ICD) trial (ClinicalTrials.gov Identifier: NCT02787785),
which enrolled patients with prior MI, diabetes and a relatively
preserved ejection fraction of 36–50%, with the aim of evaluating
the survival benefit of receiving a subcutaneous ICD when com-
pared to those receiving conventional medical therapy. Further risk
stratifiers such as heart catecholamine uptake using MIBG imag-
ing may help select eligible patients. Accordingly, a strategy trial
[The AdreView™ Myocardial Imaging for Risk Evaluation – guiding
ICD implantation (ADMIRE-ICD) trial; Clinicaltrials.gov Identifier:
NCT02656329, EudraCT #: 2015-001464-19] aimed at examining
the ability of 123I-MIBG imaging to personalize the need for pri-
mary prevention ICD therapy.33 Unfortunately, both of these trials
have recently been terminated due to slow enrolment rates, likely
because of the reluctance of investigators to challenge the current
(outdated) guidelines. Given the additional results provided in the
analysis presented herein, we would suggest that new SCD primary
prevention ICD trials are needed and should focus on patients with
residual high SCD vs. non SCD risk, as conferred by younger age
with diabetes and/or impaired kidney co-morbidities.
There is an urgent need for new risk stratification studies
following the improvement of HF medication in the past years.
Indeed, while all ICD studies have mandated ‘optimal medical
therapy’, such therapy has evolved over the last 20 years since
the seminal primary prevention ICD studies were published. As
recently pointed out,23 during this timeframe SCD rate has almost
halved in HF patients with systolic dysfunction enrolled in clinical
trials, a finding that can be ascribed to a cumulative benefit
of evidence-based medications on this mode of death. These
advances may have significantly altered the risk–benefit ratio of
ICD implantation since many of these studies were performed
prior to the introduction of modern drug therapies and prompt
revascularization techniques.
The mechanisms behind the increased SCD risk in diabetes
and/or renal dysfunction are multiple. Cardiac fibrosis is a hallmark,
commonly reported in both conditions.7,12 Fibrosis is a substrate
for malignant arrhythmia.34 Selective SCD risk enrichment may be
provided by cardiac magnetic resonance (CMR) imaging, which can
reliably assess ventricular scar and therefore potentially identify a
subgroup at increased risk of SCD.35 The ongoing CMR GUIDE
study (Clinicaltrials.gov Identifier: NCT01918215), which is cur-
rently testing a CMR-guided ICD insertion strategy for primary
prevention in patients with mild to moderate LVEF impairment (i.e.
LVEF 36–50%) and evidence of myocardial fibrosis as compared to
standard of care, should provide further information on this issue.35
Ultimately, a multiparametric approach is likely to be the key to suc-
cess for identifying post-MI patients with mild to moderate LVEF
dysfunction who would most benefit from ICD implantation.
Limitations
Our models were adjusted for an extensive number of clinical vari-
ables (n = 21). However, there may be unknown or other unmea-
sured confounding variables which were not adjusted for, and which
could have affected the observed relationships. Follow-up data on



















































































.. available and thus we cannot exclude that a certain percentage of
patients crossed over from one group to another, but we believe
this is unlikely. Randomized clinical trials included in this analysis
were conducted in the late 1990s-early 2000s, with both pharma-
cological and interventional treatment of MI having evolved since
that time. Notwithstanding, our dataset represents a unique oppor-
tunity to assess SCD risk before the era of primary prevention ICD
use. We acknowledge that SCD risk prediction cannot be regarded
as an unequivocal substitute for identifying patients most likely to
benefit from ICD implantation. However, 70% of SCDs are esti-
mated to be due to lethal arrhythmias36 (40% of SCD in the early
months after the index MI were due to recurrent MI or myocardial
rupture in a subgroup of 105 SCDs from the VALIANT trial with
available autopsy records37) and ICD therapy can effectively treat a
large proportion of SCDs (approximately 60% in a randomized clin-
ical trial meta-analysis report38). Nevertheless, the actual benefit
derived from ICD implantation may even be more difficult to assess
using ICD shock, which can be inappropriate or treat ventricu-
lar arrhythmias that could have spontaneously terminated. Lastly,
information regarding glycaemic control, diabetes duration/type or
antidiabetic drugs was not reported in the database.
Conclusions
Among high-risk post-MI patients, diabetes, impaired kidney func-
tion or both were found to be independently associated with
an increased risk of both SCD and non-SCD. There was a sim-
ilar absolute risk of SCD among LVEF > 35% patients with dia-
betes and/or impaired kidney function comparatively to patients
with LVEF 30–35% and neither of these two risk factors. How-
ever, the benefit potentially derived from ICD implantation may be
diluted by an excess in non-SCD rates, in particular among LVEF
> 35% patients with impaired kidney function with or without dia-
betes. The present findings provide strong evidence relative to the
dominant contribution of age to the competing risk of non-SCD.
Major changes in epidemiological characteristics, including ageing
and co-morbidity contributions, as well as of pharmacological treat-
ment of acute coronary syndromes and of HF have dramatically
occurred since the time of the seminal ICD trials, on which current
guidelines on ICD implantation are still based. Modern randomized
clinical trials are needed to clarify which patients may benefit most
from ICD implantation compared to conventional therapy. These
trials should typically use appropriate risk stratification, taking into
account, beyond LVEF, aetiology, age, diabetes, and renal function.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Unadjusted Kaplan–Meier survival curves in the whole
cohort. Sudden cardiac death (A) and non-sudden cardiac death (B)
rates among the four subgroups [no diabetes/estimated glomeru-
lar filtration rate (eGFR) ≥ 60 mL/min/1.73 m2, diabetes/eGFR
≥ 60 mL/min/1.73 m2, no diabetes/eGFR < 60 mL/min/1.73 m2 and
diabetes/eGFR < 60 mL/min/1.73 m2] in the whole population.
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Table S1. Balance of patient characteristics according to dia-
betes/estimated glomerular filtration rate category before and after
stabilized inverse probability of treatment weighting.
Table S2. Association of the interplay of diabetes and
impaired kidney function (estimated glomerular filtration rate
< 60 mL/min/1.73 m2) with sudden cardiac death and non-cardiac
sudden death in univariable and multivariable competing risk
model analysis considering only the period > 40 days after the
index event.
Table S3. Association of the interplay of diabetes and
impaired kidney function (estimated glomerular filtration rate
< 60 mL/min/1.73 m2) with sudden cardiac death and non-cardiac
sudden death in univariable and multivariable competing risk
model analysis among patients without available left ventricular
ejection fraction at baseline.
Table S4. Interaction between diabetes/estimated glomerular fil-
tration rate and left ventricular ejection fraction categories: com-
peting risk model analysis.
Table S5. Rate of annual sudden cardiac death and non-sudden
cardiac death rates according to diabetes and kidney function status
considering only the period > 40 days after the index event.
Table S6. Rate of annual sudden cardiac death and non-sudden
cardiac death rates according to diabetes and kidney function status
among patients without available left ventricular ejection fraction
at baseline.
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